Literature DB >> 31045223

Effects of the Dipeptidyl Peptidase 4 Inhibitor Alogliptin on Blood Pressure in Hypertensive Patients with Type 2 Diabetes Mellitus.

Shinji Kishimoto1, Yoshihiko Kinoshita2, Takeshi Matsumoto3, Tatsuya Maruhashi4, Masato Kajikawa5, Shogo Matsui4, Haruki Hashimoto4, Yuji Takaeko4, Yasuki Kihara4, Kazuaki Chayama6, Chikara Goto7, Farina Mohamad Yusoff1, Ayumu Nakashima8, Kensuke Noma1, Yukihito Higashi1,5.   

Abstract

BACKGROUND: The effects of dipeptidyl peptidase 4 (DPP-4) inhibitors on blood pressure in patients with diabetes mellitus (DM) are controversial. There is no information on the effect of DPP-4 inhibitors on blood pressure and arterial stiffness in hypertensive patients with DM. We evaluated the effects of alogliptin on blood pressure and arterial stiffness in hypertensive patients with type 2 diabetes mellitus (T2DM).
METHODS: Blood pressure and brachial-ankle pulse wave velocity (baPWV) were measured before and after 3, 6, and 12 months of treatment with alogliptin in 22 hypertensive patients with T2DM.
RESULTS: After 3, 6, and 12 months, alogliptin treatment decreased hemoglobin A1c from 7.0 ± 0.97% to 6.4 ± 0.61%, 6.3 ± 0.58%, and 6.3 ± 0.75% (P < 0.01, respectively), glucose from 8.6 ± 4.39 mmol/l to 7.05 ± 2.16, 7.05 ± 2.28, and 6.44 ± 1.50 mmol/l (P < 0.01, respectively), systolic blood pressure from 137 ± 18 mm Hg to 127 ± 13, 125 ± 15, and 120 ± 17 mm Hg (P < 0.01, respectively), diastolic blood pressure from 79 ± 13 mm Hg to 74 ± 8, 74 ± 10, and 70 ± 8 mm Hg (P < 0.01, respectively) and baPWV from 1,947 ± 349 cm/second to 1,774 ± 259, 1,856 ± 361, and 1,756 ± 286 cm/second (P < 0.01, respectively). A baseline baPWV value of 1,643 cm/second was the optimal cut-off value for patients who had reduced blood pressure after treatment with alogliptin (sensitivity of 83.3% and specificity of 75.0%).
CONCLUSIONS: Alogliptin was associated with improvements not only in glucose metabolism but also in blood pressure and arterial stiffness in hypertensive patients with T2DM. The cut-off value of baPWV may enable identification of responders of decrease in blood pressure by alogliptin in hypertensive patients with T2DM. CLINICAL TRIALS REGISTRATION: Registration Number for Clinical Trial: UMIN000007722. © American Journal of Hypertension, Ltd 2019. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  alogliptin; arterial stiffness; blood pressure; dipeptidyl peptidase 4 inhibitor; hypertension; type 2 diabetes mellitus

Year:  2019        PMID： 31045223     DOI： 10.1093/ajh/hpz065

Source DB:  PubMed          Journal:  Am J Hypertens        ISSN： 0895-7061            Impact factor:   2.689


  9 in total

Review 1.  Blood Pressure-Lowering Effect of Newer Antihyperglycemic Agents (SGLT-2 Inhibitors, GLP-1 Receptor Agonists, and DPP-4 Inhibitors).

Authors:  Charalampos I Liakos; Dimitrios P Papadopoulos; Elias A Sanidas; Maria I Markou; Erifili E Hatziagelaki; Charalampos A Grassos; Maria L Velliou; John D Barbetseas
Journal:  Am J Cardiovasc Drugs       Date:  2021-03       Impact factor: 3.571

2.  DPP4 inhibition mitigates ANG II-mediated kidney immune activation and injury in male mice.

Authors:  Ravi Nistala; Alex I Meuth; Cassandra Smith; Jianzhong An; Javad Habibi; M R Hayden; Megan Johnson; Annayya Aroor; Adam Whaley-Connell; James R Sowers; Susan C McKarns; Shawn B Bender
Journal:  Am J Physiol Renal Physiol       Date:  2021-02-01

3.  A Dipeptidyl Peptidase-4 Inhibitor Inhibits Foam Cell Formation of Macrophages in Type 1 Diabetes via Suppression of CD36 and ACAT-1 Expression.

Authors:  Michishige Terasaki; Hironori Yashima; Yusaku Mori; Tomomi Saito; Takanori Matsui; Munenori Hiromura; Hideki Kushima; Naoya Osaka; Makoto Ohara; Tomoyasu Fukui; Tsutomu Hirano; Sho-Ichi Yamagishi
Journal:  Int J Mol Sci       Date:  2020-07-07       Impact factor: 5.923

4.  Effects of dipeptidyl peptidase-4 inhibitor linagliptin versus sulphonylurea glimepiride on systemic haemodynamics in overweight patients with type 2 diabetes: A secondary analysis of an 8-week, randomized, controlled, double-blind trial.

Authors:  Jordan Kraaijenhof; Marcel H A Muskiet; Lennart Tonneijck; D Margriet Ouwens; Mark H H Kramer; Daniël H van Raalte; Mark M Smits
Journal:  Diabetes Obes Metab       Date:  2020-06-22       Impact factor: 6.577

Review 5.  Biological Context Linking Hypertension and Higher Risk for COVID-19 Severity.

Authors:  Caio A M Tavares; Matthew A Bailey; Adriana C C Girardi
Journal:  Front Physiol       Date:  2020-11-19       Impact factor: 4.566

6.  Effect of linagliptin on glucose metabolism and pancreatic beta cell function in patients with persistent prediabetes after metformin and lifestyle.

Authors:  Mildred Fátima de la Luz Alvarez-Canales; Sara Stephania Salazar-López; Diana Farfán-Vázquez; Yosceline Estrella Martínez-López; Jessica Noemí González-Mena; Lilia Marisela Jiménez-Ceja; Katya Vargas-Ortiz; María Lola Evia-Viscarra; María Luisa Montes de Oca-Loyola; Franco Folli; Alberto Aguilar-García; Rodolfo Guardado-Mendoza
Journal:  Sci Rep       Date:  2021-04-22       Impact factor: 4.379

7.  Associations between continuous glucose monitoring-derived metrics and arterial stiffness in Japanese patients with type 2 diabetes.

Authors:  Satomi Wakasugi; Tomoya Mita; Naoto Katakami; Yosuke Okada; Hidenori Yoshii; Takeshi Osonoi; Nobuichi Kuribayashi; Yoshinobu Taneda; Yuichi Kojima; Masahiko Gosho; Iichiro Shimomura; Hirotaka Watada
Journal:  Cardiovasc Diabetol       Date:  2021-01-07       Impact factor: 9.951

8.  Effect of tofogliflozin on arterial stiffness in patients with type 2 diabetes: prespecified sub-analysis of the prospective, randomized, open-label, parallel-group comparative UTOPIA trial.

Authors:  Naoto Katakami; Tomoya Mita; Hidenori Yoshii; Toshihiko Shiraiwa; Tetsuyuki Yasuda; Yosuke Okada; Keiichi Torimoto; Yutaka Umayahara; Hideaki Kaneto; Takeshi Osonoi; Tsunehiko Yamamoto; Nobuichi Kuribayashi; Kazuhisa Maeda; Hiroki Yokoyama; Keisuke Kosugi; Kentaro Ohtoshi; Isao Hayashi; Satoru Sumitani; Mamiko Tsugawa; Kayoko Ryomoto; Hideki Taki; Tadashi Nakamura; Satoshi Kawashima; Yasunori Sato; Hirotaka Watada; Iichiro Shimomura
Journal:  Cardiovasc Diabetol       Date:  2021-01-04       Impact factor: 9.951

9.  Greater glucagon-like peptide-1 responses to oral glucose are associated with lower central and peripheral blood pressures.

Authors:  Julie R Lundgren; Kristine Færch; Daniel R Witte; Anna E Jonsson; Oluf Pedersen; Torben Hansen; Torsten Lauritzen; Jens J Holst; Dorte Vistisen; Marit E Jørgensen; Signe S Torekov; Nanna B Johansen
Journal:  Cardiovasc Diabetol       Date:  2019-10-05       Impact factor: 9.951
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.